Expert Insights

Sponsored
In this video, Dr Graff talks about how the treatment landscape for CLL has evolved in recent years, especially with the introduction of acalabrutinib.
Sponsored
In this video, Dr Goy discusses recent innovations in the treatment of patients with MCL.
Anees Chagpar, MD, MSc, MPH, MA, MBA, FACS, FRCS(C), Yale School of Medicine, discusses her presentation of, "Neoadjuvant Chemotherapy for a 1.5 cm Clinically Node-Negative Breast Cancer," presented…
Anees Chagpar, MD, MSc, MPH, MA, MBA, FACS, FRCS(C), highlights notable research and presentations from the 2021 Miami Breast Cancer Conference.
Kelly Hunt, MD, MD Anderson Cancer Center, Houston, Texas, discusses findings following, "Neoadjuvant Endocrine Therapy: Optimal Strategies and Impact on Surgical Outcomes", presented at the 2021…
Fred Saad, MD, discusses the findings of ACIS, a phase 3 clinical trial of apalutamide and abiraterone acetate plus prednisone vs abiraterone alone for chemotherapy-naive CRPC.
Felix Fang, MD, University of California at San Francisco, Benioff Initiative for Prostate Cancer Research, discusses identifying molecular determinants of response to apalutamide in nonmetastatic…
Sponsored
In this video, Christina Wu, MD, discusses HER2 in patients with metastatic CRC.

Interviews

Todd Cohen, MD, highlights how certain patients with prostate cancer may be able to forgo receipt of combined ADT.
Ehab L. Atallah, MD, discusses the findings of a study which looked at outcomes after TKI cessation in patients with CML.
Laura Chow, MD, FRCPC, discusses the clinical significance of the ASCEND-7 trial, which examined the intracranial effects of ceritinib in ALK-positive NSCLC.
Jeffrey Rubnitz, MD, PhD, discusses a study on the safety and activity of venetoclax plus chemo for young patients with heavily relapsed/refractory AML.

Webcasts

Sponsored
In this video, Dr Danilov discusses the use of acalabrutinib as a treatment option for patients with CLL, SLL, and MCL.
Sponsored
In this video, Dr Graff talks about how the treatment landscape for CLL has evolved in recent years, especially with the introduction of acalabrutinib.
Sponsored
In this video, Dr Goy discusses recent innovations in the treatment of patients with MCL.
Anees Chagpar, MD, MSc, MPH, MA, MBA, FACS, FRCS(C), Yale School of Medicine, discusses her presentation of, "Neoadjuvant Chemotherapy for a 1.5 cm Clinically Node-Negative Breast Cancer," presented…

Resources

Detailed information about the presentation, diagnosis, staging, prognosis, and treatment of all types of childhood NHL and lymphoproliferative disease.
Non-Hodgkin lymphoma treatment options include chemotherapy, radiation, targeted therapy, plasmapheresis, surveillance, stem cell transplant, and surgery. Get comprehensive information on Non-Hodgkin…
Chronic myelogenous leukemia treatments include tyrosine kinase inhibitors, high-dose therapy with allogeneic transplantation, and other medications. Get detailed information about chronic…
Breast cancer is the most common cancer in pregnant and postpartum women and occurs in about 1 in 3,000 pregnant women. The average patient is between the ages of 32 years and 38 years. Because many…

Debates and Roundtables

In the third part of this roundtable, Steven Horwitz, MD; Alison Moskowitz, MD; and Barbara Pro, MD, discuss notable advancements in the standard treatment of T-cell lymphoma.
In the second part of this roundtable, Steven Horwitz, MD; Alison Moskowitz, MD; and Barbara Pro, MD, discuss the background, findings, and importance of the ECHELON-2 clinical trial.
In the first part of this roundtable, Steven Horwitz, MD; Alison Moskowitz, MD; and Barbara Pro, MD, discuss the challenges of treating patients with T-cell lymphoma.
In the second installment of this roundtable discussion, experts sat down with Oncology Learning Network to discuss use of liquid biopsies to detect treatment resistance in lung cancer, areas for…
Stay in the know.
OncNet Newsletter